JP2022549186A5 - - Google Patents

Info

Publication number
JP2022549186A5
JP2022549186A5 JP2022517731A JP2022517731A JP2022549186A5 JP 2022549186 A5 JP2022549186 A5 JP 2022549186A5 JP 2022517731 A JP2022517731 A JP 2022517731A JP 2022517731 A JP2022517731 A JP 2022517731A JP 2022549186 A5 JP2022549186 A5 JP 2022549186A5
Authority
JP
Japan
Prior art keywords
seq
binding
amino acid
binding molecule
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549186A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051513 external-priority patent/WO2021055765A2/en
Publication of JP2022549186A publication Critical patent/JP2022549186A/ja
Publication of JP2022549186A5 publication Critical patent/JP2022549186A5/ja
Pending legal-status Critical Current

Links

JP2022517731A 2019-09-19 2020-09-18 高い標的密度の細胞に対する選択性を向上させた多量体抗体 Pending JP2022549186A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902915P 2019-09-19 2019-09-19
US62/902,915 2019-09-19
PCT/US2020/051513 WO2021055765A2 (en) 2019-09-19 2020-09-18 Multimeric antibodies with enhanced selectivity for cells with high target density

Publications (2)

Publication Number Publication Date
JP2022549186A JP2022549186A (ja) 2022-11-24
JP2022549186A5 true JP2022549186A5 (cg-RX-API-DMAC7.html) 2023-08-28

Family

ID=74884716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517731A Pending JP2022549186A (ja) 2019-09-19 2020-09-18 高い標的密度の細胞に対する選択性を向上させた多量体抗体

Country Status (8)

Country Link
US (1) US20220372142A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031252A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022549186A (cg-RX-API-DMAC7.html)
CN (1) CN114616031A (cg-RX-API-DMAC7.html)
AU (1) AU2020351205A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151237A1 (cg-RX-API-DMAC7.html)
IL (1) IL291340A (cg-RX-API-DMAC7.html)
WO (1) WO2021055765A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022212191A1 (en) * 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP4011910A1 (en) * 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
ES2819870T3 (es) * 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
CA3035427A1 (en) * 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Cd20 antibodies
CA3055790A1 (en) * 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变

Similar Documents

Publication Publication Date Title
JP7140861B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
JP7701197B2 (ja) 抗薬物抗体の形成を減少させるためのii型抗cd20抗体
JP6722189B2 (ja) 単量体Fcドメイン
Yu et al. How to select IgG subclasses in developing anti-tumor therapeutic antibodies
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
CA2920117C (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
JP7611931B2 (ja) ガイダンス及びナビゲーションコントロール(gnc)抗体様タンパク質、その製造方法及び使用方法
US20220242953A1 (en) Cd3 antibody and pharmaceutical use thereof
JP2021520805A (ja) 4−1BBLを含むHer2標的化抗原結合分子
JP2022545655A5 (cg-RX-API-DMAC7.html)
KR20230141817A (ko) 이중특이 항체
CN113490690A (zh) 异源二聚体融合蛋白
JP2025506341A5 (cg-RX-API-DMAC7.html)
JP2024537096A (ja) がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
CN120530135A (zh) 抗b7h3抗体和使用方法
CN116496404A (zh) 靶向cd47和pd-l1的双特异性抗体及其应用
TW202544039A (zh) 對cd47和pdl1具有特異性的多特異性抗體、編碼其之核酸、包含其之醫藥組合物、對應其之抗體結合域、包含對應其之抗體結合域之抗體及包含編碼其之核酸的宿主細胞
HK40129779A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
HK40129137A (en) Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof
WO2025092742A1 (zh) 结合bcma的抗体以及包含其的多特异性抗体
HK40082471A (en) Binding protein having h2l2 and hcab structures
HK40073540A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
HK40073540B (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法